SCHEDULE 13G/A: Morgan Stanley Reduces Stake in Treace Medical Concepts Below 5%

Morgan Stanley has filed an amended Schedule 13G, indicating its beneficial ownership in Treace Medical Concepts, Inc. has fallen to 3.4% as of December 31, 2024, no longer exceeding the 5% threshold.

Summary

• Morgan Stanley, the reporting person, has filed an Amendment No. 1 to Schedule 13G for Treace Medical Concepts, Inc. (Issuer: TREACE MEDICAL CONCEPTS, INC., CUSIP: 89455T109).
• As of December 31, 2024, Morgan Stanley's aggregate beneficial ownership in Treace Medical Concepts, Inc. common stock is 2,091,809 shares.
• This amount represents 3.4% of the class of securities, which is below the 5% threshold that requires ongoing reporting.
• Morgan Stanley holds 0.00 shares with sole voting power and 2,074,734.00 shares with shared voting power.
• Morgan Stanley holds 0.00 shares with sole dispositive power and 2,091,809.00 shares with shared dispositive power.
• The filing indicates that Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.

Sentiment

Score: 4

Explanation: The reduction of a significant institutional stake below the 5% threshold is generally viewed as a neutral to slightly negative signal, as it indicates a decrease in a major investor's position in the company.

Negatives

• Morgan Stanley's beneficial ownership in Treace Medical Concepts, Inc. has decreased to 3.4%, falling below the 5% threshold, which may be perceived as a reduction in institutional confidence or a strategic rebalancing by a major investor.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the reduction in Morgan Stanley's stake as a decrease in institutional confidence, potentially influencing market sentiment and share price.

Key Dates

Recommendation

Keywords

Morgan Stanley, Treace Medical Concepts, Schedule 13G, beneficial ownership, institutional investment, common stock, stake reduction, SEC filing